RhumbLine Advisers
LJPC

RhumbLine Advisers’s La Jolla Pharmaceutical Company LJPC Stock Holding History

RhumbLine Advisers’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,411
Closed -$104K – 3225
2021
Q1 		$104K Hold
24,411
– – ﹤0.01% 2933
2020
Q4 		$95K Buy
24,411
+1,320
+6% +$5.64K ﹤0.01% 2971
2020
Q3 		$93K Sell
23,091
-3,505
-13% -$14.5K ﹤0.01% 2880
2020
Q2 		$113K Sell
26,596
-221
-0.8% -$1.35K ﹤0.01% 2940
2020
Q1 		$113K Hold
26,817
– – ﹤0.01% 2750
2019
Q4 		$105K Buy
26,817
+48
+0.2% +$283 ﹤0.01% 2870
2019
Q3 		$236K Sell
26,769
-185
-0.7% -$1.75K ﹤0.01% 2688
2019
Q2 		$249K Buy
26,954
+207
+0.8% +$1.56K ﹤0.01% 2698
2019
Q1 		$172K Sell
26,747
-847
-3% -$5.52K ﹤0.01% 2782
2018
Q4 		$260K Buy
27,594
+9,064
+49% +$136K ﹤0.01% 2608
2018
Q3 		$373K Sell
18,530
-1,325
-7% -$34.6K ﹤0.01% 2400
2018
Q2 		$579K Buy
19,855
+3,995
+25% +$123K ﹤0.01% 2239
2018
Q1 		$472K Sell
15,860
-230
-1% -$7.42K ﹤0.01% 2236
2017
Q4 		$518K Sell
16,090
-4,157
-21% -$136K ﹤0.01% 2217
2017
Q3 		$704K Buy
20,247
+235
+1% +$7.56K ﹤0.01% 2157
2017
Q2 		$596K Buy
20,012
+3,618
+22% +$104K ﹤0.01% 2210
2017
Q1 		$489K Buy
16,394
+1,554
+10% +$39.7K ﹤0.01% 2263
2016
Q4 		$260K Buy
14,840
+1,025
+7% +$19.6K ﹤0.01% 2556
2016
Q3 		$329K Buy
13,815
+220
+2% +$4.15K ﹤0.01% 2431
2016
Q2 		$218K Sell
13,595
-707
-5% -$12.7K ﹤0.01% 2696
2016
Q1 		$299K Buy
14,302
+1,040
+8% +$18.5K ﹤0.01% 2532
2015
Q4 		$358K Buy
13,262
+3,115
+31% +$84.9K ﹤0.01% 2459
2015
Q3 		$282K Buy
10,147
+527
+5% +$16.6K ﹤0.01% 2589
2015
Q2 		$236K Buy
+9,620
New +$198K ﹤0.01% 2794

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's LJPC Position: Q2 2021 in Review

RhumbLine Advisers sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2021, closing a stake of 24,411 shares — an estimated $104K sold.

RhumbLine Advisers first reported a position in LJPC in Q2 2015 and held it in 24 quarters. The position peaked at $704K in Q3 2017. 62 funds tracked by Wall St. Rank hold LJPC as of Q2 2021.

  • RhumbLine Advisers reported no remaining La Jolla Pharmaceutical Company position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 24,411 La Jolla Pharmaceutical Company shares in Q2 2021, an estimated $104K.
  • RhumbLine Advisers first reported a position in La Jolla Pharmaceutical Company in Q2 2015 and held it in 24 quarters.
  • RhumbLine Advisers's La Jolla Pharmaceutical Company position peaked at $704K in Q3 2017.
  • 62 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.